Report: five companies would take brunt of Trump Part B proposal

The cost of an international reference pricing scheme the Trump administration has proposed for Medicare Part B would fall most heavily on five companies: Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Amgen Inc. (NASDAQ:AMGN), Bristol-Myers Squibb Co. (NYSE:BMY), Genentech Inc. and Roche (SIX:ROG; OTCQX:RHHBY), according to a PricewaterhouseCoopers report.

According to a CMS report released when the administration announced the plan in October, the companies each stand to lose over $640 million a year in revenue if the international pricing index (IPI) is implemented as planned (see “Trump Administration to Peg Part B Payments to International Pricing”)...